Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants

Blood

Volumn 121, Issue 16, 2013, Pages 3261-3266

  Jackman, Rachael P ^a   Deng, Xutao ^a   Bolgiano, Douglas ^b   Lebedeva, Mila ^a   Heitman, John W ^a   Busch, Michael P ^a,c   Slichter, Sherrill J ^b,d   Norris, Philip J ^a,c  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ANTIBODY; HLA ANTIBODY; HUMAN PLATELET ANTIGEN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; HLA ANTIGEN; THROMBOCYTE ANTIGEN;

ANTIBODY BLOOD LEVEL; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT RECIPIENT; HUMAN; LYMPHOCYTOTOXICITY; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; BLOOD; IMMUNOLOGY; THROMBOCYTE;

ANTIBODIES; ANTIGENS, HUMAN PLATELET; BLOOD PLATELETS; HLA ANTIGENS; HUMANS; PLATELET TRANSFUSION;

MLCS; MLOWN;

EID: 84879156555     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-472779     Document Type: Article

References (38)

1. Howard JE, Perkins HA. The natural history of alloimmunization to platelets. Transfusion. 1978; 18(4):496-503.
2. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105(10):4106-4114.
3. Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood. 1988;72(3):964-969.
4. Dutcher JP, Schiffer CA, Aisner J, et al. Alloimmunization following platelet transfusion: the absence of a dose-response relationship. Blood. 1981;57(3):395-398.
5. Fisher M, Chapman JR, Ting A, et al. Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions. Vox Sang. 1985;49(5):331-335.
6. Murphy MF, Metcalfe P, Thomas H, et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol. 1986;62(3):529-534.
7. Schiffer CA, Dutcher JP, Aisner J, et al. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood. 1983;62(4):815-820.
8. van Marwijk Kooy M, van Prooijen HC, Moes M, et al. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood. 1991;77(1):201-205.
9. Karpinski M, Pochinco D, Dembinski I, et al. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol. 2004;15(3):818-824.
10. Fauchet R, Genetet B, Gueguen M, et al. Transfusion therapy and HLA antibody response in patients undergoing open heart surgery. Transfusion. 1982;22(4):320-322.
11. Holohan TV, Terasaki PI, Deisseroth AB. Suppression of transfusion-related alloimmunization in intensively treated cancer patients. Blood. 1981;58(1):122-128.
12. Oksanen K, Kekomäki R, Ruutu T, et al. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components-a randomized trial. Transfusion. 1991;31(7):588-594.
13. Slichter SJ, Bolgiano D, Kao KJ, et al. Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products. Transfus Med Rev. 2011;25(2):102-110.
14. Sniecinski I, O’Donnell MR, Nowicki B, et al. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood. 1988;71(5):1402-1407.
15. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood. 1995;85(3):824-828.
16. Payne R, Rolfs MR. Further observations on leukoagglutinin transfusion reactions in women: with special reference to leukoagglutinin transfusion reactions in women. Am J Med. 1960;29:449-458.
17. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337(26):1861-1869.
18. Phelan DL, Rodey GE, Anderson CB. The development and specificity of antiidiotypic antibodies in renal transplant recipients receiving single-donor blood transfusions. Transplantation. 1989;48(1):57-60.
19. Terasaki PI, McClelland JD. Microdroplet Assay of Human Serum Cytotoxins. Nature. 1964;204: 998-1000.
20. Carrick DM, Johnson B, Kleinman SH, et al. NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II). Agreement among HLA antibody detection assays is higher in ever-pregnant donors and improved using a consensus cutoff. Transfusion. 2011;51(5):1105-1116.
21. Pei R, Lee J, Chen T, et al. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol. 1999;60(12):1293-1302.
22. Uboldi de Capei M, Praticò L, Curtoni ES. Comparison of different techniques for detection of anti-HLA antibodies in sera from patients awaiting kidney transplantation. Eur J Immunogenet. 2002;29(5):379-382.
23. Wahrmann M, Exner M, Haidbauer B, et al. [C4d]FlowPRA screening-a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Hum Immunol. 2005; 66(5):526-534.
24. Fadeyi E, Adams S, Peterson B, et al. Analysis of a high-throughput HLA antibody screening assay for use with platelet donors. Transfusion. 2008; 48(6):1174-1179.
25. Lopes LB, Fabron-Jr A, Chiba AK, et al. Impact of using different laboratory assays to detect human leukocyte antigen antibodies in female blood donors. Transfusion. 2010;50(4):902-908.
26. Worthington JE, Robson AJ, Sheldon S, et al. A comparison of enzyme-linked immunoabsorbent assays and flow cytometry techniques for the detection of HLA specific antibodies. Hum Immunol. 2001;62(10):1178-1184.
27. Kickler T, Kennedy SD, Braine HG. Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion. 1990;30(7):622-625.
28. Kiefel V, König C, Kroll H, et al. Platelet alloantibodies in transfused patients. Transfusion. 2001;41(6):766-770.
29. Sanz C, Freire C, Alcorta I, et al. Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion. 2001;41(6): 762-765.
30. Kurz M, Knöbl P, Kalhs P, et al. Platelet-reactive HLA antibodies associated with low posttransfusion platelet increments:a comparison between the monoclonal antibody-specific immobilization of platelet antigens assay and the lymphocytotoxicity test. Transfusion. 2001;41(6):771-774.
31. Novotny VM, van Doorn R, Witvliet MD, et al. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood. 1995;85(7):1736-1741.
32. Kekomäki S, Volin L, Koistinen P, et al. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia. Eur J Haematol. 1998;60(2):112-118.
33. Langenscheidt F, Kiefel V, Santoso S, et al. Platelet transfusion refractoriness associated with two rare platelet-specific alloantibodies (anti-Baka and anti-PlA2) and multiple HLA antibodies. Transfusion. 1988;28(6):597-600.
34. Pappalardo PA, Secord AR, Quitevis P, et al. Platelet transfusion refractoriness associated with HPA-1a (Pl (A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion. 2001;41(8):984-987.
35. Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion. 2009;49(9):1825-1835.
36. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statisitical Computing; 2011
37. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142(3):348-360.
38. Ishida A, Handa M, Wakui M, et al. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation-a prospective analysis. Transfusion. 1998;38(9):839-847.